Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.
Nakamura Y., Taniguchi H., Ikeda M., Bando H., Kato K., Morizane C., Esaki T., Komatsu Y., Kawamoto Y., Takahashi N., Ueno M., Kagawa Y., Nishina T., Kato T., Yamamoto Y., Furuse J., Denda T., Kawakami H., Oki E., Nakajima T., Nishida N., Yamaguchi K., Yasui H., Goto M., Matsuhashi N., Ohtsubo K., Yamazaki K., Tsuji A., Okamoto W., Tsuchihara K., Yamanaka T., Miki I., Sakamoto Y., Ichiki H., Hata M., Yamashita R., Ohtsu A., Odegaard JI., Yoshino T.
Comprehensive genomic profiling enables genomic biomarker detection in advanced solid tumors. Here, to evaluate the utility of circulating tumor DNA (ctDNA) genotyping, we compare trial enrollment using ctDNA sequencing in 1,687 patients with advanced gastrointestinal (GI) cancer in SCRUM-Japan GOZILA (no. UMIN000016343), an observational ctDNA-based screening study, to enrollment using tumor tissue sequencing in the same centers and network (GI-SCREEN, 5,621 patients). ctDNA genotyping significantly shortened the screening duration (11 versus 33 days, P